 |
Return Create A Forum - Home |
 |
--------------------------------------------------------- |
|
MS Speaks |
 |
https://msspeaks.createaforum.com |
|
--------------------------------------------------------- |
|
***************************************************** |
|
Return to: NOVANTRONE (mitoxantrone) |
|
***************************************************** |
|
#Post#: 701-------------------------------------------------- |
|
(Abst.) Therapy-related acute leukemia w/Novantrone...limiting t |
|
he risk |
|
By: agate Date: March 30, 2015, 9:54 am |
|
--------------------------------------------------------- |
|
From Multiple Sclerosis Journal, March 30, 2015: |
|
[quote]Therapy-related acute leukaemia with mitoxantrone: Four |
|
years on, what is the risk and can it be limited? |
|
Richard Ellis |
|
The Walton Centre for Neurology and Neurosurgery, UK |
|
Sean Brown |
|
Countess of Chester, Chester, UK |
|
Mike Boggild |
|
Townsville Hospital, Queensland, Australia |
|
The Walton Centre for Neurology and Neurosurgery, Lower Lane, |
|
Fazakerley, Liverpool, L9 7LJ, UK [email protected] |
|
Therapy-related acute leukaemia (TRAL) is a significant concern, |
|
when considering treatment with mitoxantrone for multiple |
|
sclerosis (MS). We re-evaluated the literature, identifying all |
|
case reports and series of > 50 patients reporting TRAL cases in |
|
MS. TRAL was diagnosed in 0.73% of the 12,896 patients |
|
identified. Median onset was 22 months following treatment. We |
|
calculated a number needed to harm of 137.5 exposed patients, |
|
significantly higher than our 2008 analysis. |
|
We found that 82.8% of patients were exposed to > 60 mg/m2 with |
|
a relative risk of 1.85 (p = 0.018) compared to < 60mg/m2, |
|
strongly suggesting a relationship to dose. MS treatment |
|
regimens which limit the mitoxantrone dose to < 60mg/m2 reduce |
|
the risk of TRAL.[/quote] |
|
***************************************************** |
